focus -WSS

focus

author：comprehensive 2025-08-25 08:45:00 - browse：66

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Donald Trump's relentless attacks on special counsel Jack Smith

leisure time

WSS

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Disclosing genetic information: not as worrisome as once feared

3 hurdles to bringing medical devices to the U.S. market

Faced with fears of OxyContin misuse, sales reps touted its safety

After John Oliver segment, STAT readers share their opioid

The history of OxyContin, told through Purdue Pharma documents

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Psychedelics group wrestles with new pharma identity

Weight bias in eating disorder treatment complicated by new weight loss drugs

Cancer drug shortages should be causing more outrage

Why are elite athletes different? Take a look at their microbes

The high cost of giving birth even with insurance

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

What does generative AI mean for health care? We asked experts

Timeline: Special counsel's investigation into Trump's handling of classified documents

Psychedelics group wrestles with new pharma identity

Why we need to separate burnout from moral injury in health care

hotspot

Genentech weighs delaying cancer therapy after drug pricing law

#NeedHerScience: shining a light on gender disparities in medicine

Pharma budget tightening trickles down to Doximity

Newly revealed memo details efforts to keep Trump in power following election loss

Donald Trump's relentless attacks on special counsel Jack Smith

Faced with fears of OxyContin misuse, sales reps touted its safety

focus

explore

leisure time

knowledge